EHC

Encompass Health Corporation [EHC]

Support and Resistance Basics

What is MACD and how to read it?

How RSI can help?

Stock Summary

Earnings have grown 10.27% per last year.

Earnings are expected to rise 20.27% next year

EHC's dividend payments are well covered by cash flows with cash payout ratio of 34.09%.

EPS has been decreasing for the past 3 quarters (Quarter statements)

Profit margins (0.06%) are lower than the previous year (0.08%)

EHC has less than 1 year of cash runway

Debt-to-Equity ratio of 1.72 is considered moderate, deeper research suggested.

Top Correlated Resources

EHC

Top 10 Correlated ETFs

EHC

Top 10 Correlated Stocks

EHC

In the News

02:18 13 Aug 2022 EHC

Encompass Health (EHC) Up 4.7% Despite Q2 Earnings Miss

Encompass Health (EHC) intends to open three additional de novo locations and increase the bed count by 20 in existing facilities this year.

08:06 13 Aug 2022 EHC

Encompass Health Encompasses Quality, Defensibility After Q2 FY22

Encompass Health posted Q2 FY22 earnings last week with downsides relative to consensus at the top and bottom line. Despite this, FCF remained buoyant and the company did recognize growth in most segments.

03:18 13 Aug 2022 EHC

Encompass Health Corporation (EHC) CEO Mark Tarr on Q2 2022 Results - Earnings Call Transcript

Encompass Health Corporation (NYSE:EHC ) Q2 2022 Earnings Conference Call August 2, 2022 10:00 AM ET Company Participants Mark Miller - Chief IR Officer Mark Tarr - President and CEO Doug Coltharp - CFO Patrick Darby - General Counsel and Corporate Secretary Conference Call Participants Andrew Mok - UBS Joanna Gajuk - Bank of America Brian Tanquilut - Jefferies John Ransom - Raymond James Pito Chickering - Deutsche Bank Matthew Borsch - BMO Capital Markets Sarah James - Barclays Operator Good morning, everyone, and welcome to Encompass Health's Second Quarter 2022 Earnings Conference Call. [Operator Instructions] I will now turn the call over to Mark Miller, Encompass Health's Chief Investor Relations Officer.

08:08 13 Aug 2022 EHC

Encompass Health (EHC) Q2 Earnings and Revenues Miss Estimates

Encompass Health (EHC) delivered earnings and revenue surprises of -8.25% and 1.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

11:35 13 Aug 2022 EHC

Analysts Estimate Encompass Health (EHC) to Report a Decline in Earnings: What to Look Out for

Encompass Health (EHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

06:25 13 Aug 2022 EHC

Encompass Health (EHC) to Build New Rehab Unit in Missouri

Encompass Health (EHC) and BJC HealthCare's new rehabilitation hospital is expected to come online in 2024.

12:42 13 Aug 2022 EHC

Encompass Health (EHC) Opens EHR-Backed Hospital in Florida

Encompass Health (EHC) takes its U.S. inpatient rehabilitation hospital count to 150 with the opening of a hospital in Florida integrated with the sound EHR system of Oracle Cerner.

05:43 13 Aug 2022 EHC

Encompass Health (EHC) Forms JV With NCH Healthcare in Naples

The NCH Healthcare System's board grants approval to invest in the joint venture with Encompass Health (EHC).

10:16 13 Aug 2022 EHC

Four value-stock picks from a fund manager who steers clear of the energy sector

Jensen Investment Management follows a simple rule for initial screenings of stocks: Companies need to have achieved returns on equity (ROE) of at least 15% annually, for at least 10 consecutive years.

04:12 13 Aug 2022 EHC

Encompass Health (EHC) Plans to Distribute Enhabit Shares

Every Encompass Health (EHC) shareholder will receive one Enhabit common share for every two EHC common shares held.

Financial details

Company Rating

Strong Buy

Market Cap

5.28B

Income

327.8M

Revenue

5.27B

Book val./share

20.19

Cash/share

1.88

Dividend

1.12

Dividend %

2.08%

Employees

28K

Optionable

Shortable

Yes

Earnings

25 Oct 2022

P/E

16.46

Forward P/E

11.21

PEG

10.99

P/S

1.01

P/B

2.67

P/C

28.63

P/FCF

26.5

Quick Ratio

1.01

Current Ratio

1.24

Debt / Equity

1.72

LT Debt / Equity

1.35

EPS (TTM)

3.3

EPS next Y

4.8

EPS next Q

1.2

EPS this Y

44.6%

EPS next Y

45.45%

EPS next 5Y

45.45%

EPS last 5Y

8.74%

Revenue last 5Y

5.5%

Revenue Q/Q

-0.23%

EPS Q/Q

-44.32%

SMA20

8.97%

SMA50

2.55%

SMA100

-3.44%

Inst Own

92.98%

Inst Trans

2.15%

ROA

ROE

17%

ROC

0.12%

Gross Margin

96%

Oper. Margin

14%

Profit Margin

Payout

34%

Shs Outstand

99.78M

Shs Float

97.79M

Target Price

88.25

52W Range

42.187748-64.797134

52W High

-15.91%

52W Low

+28.14%

RSI

68.44

Rel Volume

0.71

Avg Volume

1.03M

Volume

726.02K

Perf Week

0.88%

Perf Month

20.7%

Perf Quarter

2.64%

Perf Half Y

6.22%

Beta

1.00085

Volatility

0.58%, 1.99%

Prev Close

1.8%

Price

53.82

Change

1.45%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31
Revenue per share	41.82	43.69	46.99	47.1	51.94
Net income per share	2.74	2.99	3.66	2.88	4.18
Operating cash flow per share	7.01	7.79	6.48	7.15	7.26
Free cash flow per share	4.4	5.02	2.36	3.01	1.67
Cash per share	0.58	0.71	0.97	2.27	0.56
Book value per share	12.61	13.04	13.8	16.11	19.38
Tangible book value per share	-10.15	-10.08	-11.11	-7.91	-4.53
Share holders equity per share	12.61	13.04	13.8	16.11	19.38
Interest debt per share	29.16	27.19	33.29	37.8	37.55
Market cap	3.97B	5.19B	6.02B	6.31B	4.87B
Enterprise value	6.5B	7.64B	9.03B	9.63B	8.35B
P/E ratio	15.5	17.77	16.79	22.19	11.81
Price to sales ratio	1.01	1.21	1.31	1.36	0.95
POCF ratio	6.05	6.81	9.48	8.95	6.8
PFCF ratio	9.64	10.56	26.05	21.27	29.57
P/B Ratio	3.36	4.07	4.45	3.97	2.55
PTB ratio	3.36	4.07	4.45	3.97	2.55
EV to sales	1.66	1.79	1.96	2.07	1.63
Enterprise value over EBITDA	8.6	10.08	10.59	11.81	8.58
EV to operating cash flow	9.88	10.02	14.21	13.66	11.67
EV to free cash flow	15.76	15.53	39.06	32.47	50.74
Earnings yield	0.06	0.06	0.06	0.05	0.08
Free cash flow yield	0.1	0.09	0.04	0.05	0.03
Debt to equity	2.15	1.94	2.24	2.18	1.81
Debt to assets	0.71	0.7	0.72	0.69	0.65
Net debt to EBITDA	3.34	3.23	3.53	4.07	3.58
Current ratio	1.36	0.98	1.05	1.32	1.23
Interest coverage	4.21	4.63	4.34	3.52	4.9
Income quality	2.56	2.61	1.77	2.48	1.74
Dividend Yield	0.02	0.02	0.02	0.02	0.02
Payout ratio	0.36	0.34	0.3	0.39	0.27
Sales general and administrative to revenue	0.61	0.62	0.63	0.63	0.62
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0.49	0.49	0.46	0.43	0.41
Capex to operating cash flow	-0.37	-0.35	-0.64	-0.58	-0.77
Capex to revenue	-0.06	-0.06	-0.09	-0.09	-0.11
Capex to depreciation	-1.33	-1.35	-1.85	-1.68	-2.15
Stock based compensation to revenue	0.01	0.02	0.02	0.01	0.01
Graham number	27.86	29.6	33.71	32.32	42.7
ROIC	0.15	0.15	0.13	0.11	0.13
Return on tangible assets	0.1	0.11	0.11	0.08	0.1
Graham Net	-32.66	-32.67	-39.93	-38.77	-39.56
Working capital	184.7M	-10.4M	34.8M	231.3M	172.6M
Tangible asset value	-951.1M	-987.2M	-1.09B	-780M	-446.2M
Net current asset value	-2.77B	-2.96B	-3.63B	-3.53B	-3.54B
Invested capital	2.18	1.97	2.29	2.23	1.85
Average receivables	522.45M	520.25M	539.45M	572.8M	626.55M
Average payables	96.7M	102.5M	104.8M	115M	126.3M
Average inventory	0	0	0	0	0
Days sales outstanding	43.97	39.91	40.11	45.02	48.48
Days payables outstanding	191.67	206.99	205.65	209.35	239.96
Days of inventory on hand	0	0	0	0	0
Receivables turnover	8.3	9.15	9.1	8.11	7.53
Payables turnover	1.9	1.76	1.77	1.74	1.52
Inventory turnover	0	0	0	0	0
ROE	0.22	0.23	0.27	0.18	0.22
Capex per share	-2.61	-2.76	-4.12	-4.14	-5.59

Quarterly Fundamentals Overview

Last date of statement is 2022-06-30 for Q2

Metric	2021-06-30	2021-09-30	2021-12-31	2022-03-31	2022-06-30
Revenue per share	13.01	12.98	13.32	13.44	13.41
Net income per share	1.14	1.01	0.93	0.88	0.49
Operating cash flow per share	2.58	1.79	1.25	2.21	2.47
Free cash flow per share	1.33	0.52	-0.79	1.05	1.26
Cash per share	0.74	0.96	0.55	0.95	1.88
Book value per share	17.8	18.61	19.31	19.89	20.19
Tangible book value per share	-6.45	-5.54	-4.51	-3.79	-3.13
Share holders equity per share	17.8	18.61	19.31	19.89	20.19
Interest debt per share	35.04	35.32	36.14	35.79	36.21
Market cap	6.15B	5.91B	5.14B	5.61B	4.42B
Enterprise value	9.5B	9.27B	8.62B	9.03B	7.77B
P/E ratio	13.56	14.78	14.03	16.03	22.71
Price to sales ratio	4.77	4.6	3.9	4.21	3.32
POCF ratio	24.02	33.28	41.52	25.64	18.08
PFCF ratio	46.56	115.88	-65.81	54.12	35.42
P/B Ratio	3.49	3.21	2.69	2.84	2.21
PTB ratio	3.49	3.21	2.69	2.84	2.21
EV to sales	7.38	7.22	6.54	6.77	5.84
Enterprise value over EBITDA	36.82	38.81	37.66	40.22	34.43
EV to operating cash flow	37.12	52.21	69.65	41.24	31.76
EV to free cash flow	71.97	181.81	-110.41	87.06	62.2
Earnings yield	0.02	0.02	0.02	0.02	0.01
Free cash flow yield	0.02	0.01	-0.02	0.02	0.03
Debt to equity	1.88	1.82	1.81	1.74	1.72
Debt to assets	0.67	0.66	0.65	0.64	0.64
Net debt to EBITDA	13	14.07	15.21	15.22	14.83
Current ratio	1.07	1.15	1.23	1.26	1.24
Interest coverage	5.24	5	4.5	4.64	2.67
Income quality	2.26	1.78	1.35	2.5	5.02
Dividend Yield	0	0	0.01	0.01	0.01
Payout ratio	0.25	0.28	0.3	0.33	0.57
Sales general and administrative to revenue	0.61	0.62	0.64	0.63	0.64
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0.43	0.42	0.41	0.41	0.4
Capex to operating cash flow	-0.48	-0.71	-1.63	-0.53	-0.49
Capex to revenue	-0.1	-0.1	-0.15	-0.09	-0.09
Capex to depreciation	-1.95	-1.95	-3.07	-1.74	-1.74
Stock based compensation to revenue	0.01	0.01	0.01	0.01	0.01
Graham number	21.41	20.57	20.05	19.87	14.93
ROIC	0.04	0.03	0.03	0.03	0.03
Return on tangible assets	0.03	0.03	0.02	0.02	0.01
Graham Net	-38.99	-38.94	-39.4	-38.77	-38.88
Working capital	54.8M	115.9M	172.6M	195.2M	197M
Tangible asset value	-638.8M	-548.4M	-446.2M	-375.5M	-310.3M
Net current asset value	-3.54B	-3.52B	-3.54B	-3.5B	-3.51B
Invested capital	1.95	1.88	1.85	1.78	1.76
Average receivables	655.5M	660.65M	681.9M	683.5M	671.1M
Average payables	146.2M	148.35M	142.45M	147.3M	142.8M
Average inventory	0	0	0	0	0
Days sales outstanding	43.86	44.68	46.43	46.13	44.56
Days payables outstanding	261.18	252.74	228.49	236.31	235.74
Days of inventory on hand	0	0	0	0	0
Receivables turnover	2.05	2.01	1.94	1.95	2.02
Payables turnover	0.34	0.36	0.39	0.38	0.38
Inventory turnover	0	0	0	0	0
ROE	0.06	0.05	0.05	0.04	0.02
Capex per share	-1.25	-1.28	-2.04	-1.16	-1.21

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 1.03M
Market Capitalization 5.28B
Employee 28K
CEO Mr. Mark Tarr
Headquarters Birmingham,ALABAMA,US
IPO Date 1986-09-24
Website https://www.encompasshealth.com

Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations. The Home Health and Hospice segment provides home health and hospice services primarily in the Southeast and Texas. Its home health services include a range of Medicare-certified home nursing services to adult patients in need of care comprising skilled nursing, medical social work, and home health aide services, as well as physical, occupational, speech therapy, and others. This segment's hospice services comprise in-home services to terminally ill patients and their families. As of June 1, 2022, it operated 149 hospitals, 252 home health locations, and 99 hospice locations in 42 states and Puerto Rico. The company was formerly known as HealthSouth Corporation and changed its name to Encompass Health Corporation in January 2018. Encompass Health Corporation was founded in 1983 and is based in Birmingham, Alabama.